Stock Scorecard



Stock Summary for Pfizer Inc (PFE) - $24.88 as of 11/19/2025 9:17:44 PM EST

Total Score

12 out of 30

Safety Score

64 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PFE

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PFE

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PFE

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PFE

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PFE (64 out of 100)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 6
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 8
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 9
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for PFE

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates 11/20/2025 6:00:00 AM
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025 - Ascentage Pharma Group ( NASDAQ:AAPG ) 11/19/2025 1:00:00 PM
Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery 11/19/2025 12:08:00 PM
Saudi Arabia To Buy Nearly 300 US Tanks In Defense Deal, Boosts Investment Commitment To $1 Trillion - Lockheed Martin ( NYSE:LMT ) , General Dynamics ( NYSE:GD ) 11/19/2025 8:41:00 AM
Can AI Drive Peloton's Comeback? 11/18/2025 7:23:00 PM
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B 11/18/2025 4:03:00 PM
Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock? 11/18/2025 3:59:00 PM
2 No-Brainer Healthcare Stocks to Buy Now 11/18/2025 11:45:00 AM
Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy? 11/18/2025 2:10:00 AM
Novo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control - Novo Nordisk ( NYSE:NVO ) 11/17/2025 3:11:00 PM

Financial Details for PFE

Company Overview

Ticker PFE
Company Name Pfizer Inc
Country USA
Description Pfizer Inc. is a preeminent global pharmaceutical and biotechnology firm based in New York City, with a storied legacy of innovation since its founding in 1849. The company is renowned for its diverse therapeutic portfolio, which spans immunology, oncology, and cardiology, and is supported by a robust pipeline of groundbreaking treatments. Notably, Pfizer's rapid development of the COVID-19 vaccine underscored its agility in research and commitment to addressing urgent public health needs. Through strategic collaborations and ongoing investment in cutting-edge research, Pfizer is poised to sustain its leadership position in the healthcare sector while continuing to improve health outcomes worldwide.
Sector Name HEALTHCARE
Industry Name DRUG MANUFACTURERS - GENERAL
Most Recent Quarter 9/30/2025
Next Earnings Date 2/3/2026

Stock Price History

Last Day Price 24.88
Price 4 Years Ago 48.05
Last Day Price Updated 11/19/2025 9:17:44 PM EST
Last Day Volume 61,018,288
Average Daily Volume 79,880,130
52-Week High 27.21
52-Week Low 19.83
Last Price to 52 Week Low 25.47%

Valuation Measures

Trailing PE 14.58
Industry PE 28.78
Sector PE 115.35
5-Year Average PE 10.17
Free Cash Flow Ratio 103.67
Industry Free Cash Flow Ratio 29.57
Sector Free Cash Flow Ratio 27.55
Current Ratio Most Recent Quarter 1.28
Total Cash Per Share 0.24
Book Value Per Share Most Recent Quarter 16.32
Price to Book Ratio 1.54
Industry Price to Book Ratio 10.15
Sector Price to Book Ratio 33.20
Price to Sales Ratio Twelve Trailing Months 2.27
Industry Price to Sales Ratio Twelve Trailing Months 4.08
Sector Price to Sales Ratio Twelve Trailing Months 16.69
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 5,685,708,000
Market Capitalization 141,460,415,040
Institutional Ownership 67.27%

Dividends

Ex-Dividend Date 11/7/2025
Previous Dividend Amount 0.4300
Current Dividend Amount 0.4300
Total Years Dividend Increasing Dividend Contender - Increasing for 14 Years
Trailing Annual Dividend Rate 1.72
Trailing Annual Dividend Yield 6.67%
Forward Annual Dividend Rate 1.72
Forward Annual Dividend Yield 6.67%
5-Year Dividend Payments Count 20
3-Year Average Dividend Yield 6.64%
5-Year Average Dividend Yield 5.06%
1-Year Dividend Growth Rate Percentage 2.38%
3-Year Dividend Growth Rate Percentage 2.41%
5-Year Dividend Growth Rate Percentage 2.47%
All-Time Dividend Growth Rate Percentage 8.62%
Dividend Payout Ratio 100.00%

Income Statement

Quarterly Earnings Growth YOY -21.30%
Annual Earnings Growth 276.00%
Reported EPS 12 Trailing Months 1.72
Reported EPS Past Year 2.30
Reported EPS Prior Year 2.84
Net Income Twelve Trailing Months 9,821,000,000
Net Income Past Year 8,020,000,000
Net Income Prior Year 2,133,000,000
Quarterly Revenue Growth YOY -5.90%
5-Year Revenue Growth 9.10%
Operating Margin Twelve Trailing Months 35.30%

Balance Sheet

Total Cash Most Recent Quarter 1,343,000,000
Total Cash Past Year 1,043,000,000
Total Cash Prior Year 2,853,000,000
Net Cash Position Most Recent Quarter -55,202,000,000
Net Cash Position Past Year -55,660,000,000
Long Term Debt Past Year 56,703,000,000
Long Term Debt Prior Year 60,499,000,000
Total Debt Most Recent Quarter 56,545,000,000
Equity to Debt Ratio Past Year 0.61
Equity to Debt Ratio Most Recent Quarter 0.62
Total Stockholder Equity Past Year 88,203,000,000
Total Stockholder Equity Prior Year 89,014,000,000
Total Stockholder Equity Most Recent Quarter 92,801,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 10,376,000,000
Free Cash Flow Per Share Twelve Trailing Months 1.82
Free Cash Flow Past Year 9,835,000,000
Free Cash Flow Prior Year 4,793,000,000

Options

Put/Call Ratio 0.41
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.24
MACD Signal 0.08
20-Day Bollinger Lower Band 22.74
20-Day Bollinger Middle Band 24.39
20-Day Bollinger Upper Band 26.04
Beta 0.42
RSI 56.12
50-Day SMA 23.90
150-Day SMA 27.02
200-Day SMA 30.52

System

Modified 11/18/2025 6:39:29 AM EST